You have read all your free articles, to continue reading subscribe to read the rest of this content.
The company is launching Rexulti (brexiprazole) for the treatment of adult patients with schizophrenia in Switzerland from 1 January 2019. The launch is the first in a sequence that will see the treatment made available in other European countries during 2019 and 2020. “We are delighted to bAlready a subscriber…
The European Commission has approved Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The European approval makes Adtralza the first high affinity, fully human monoclonal antibody approved to specifically Already a subscriber Login You have read all your free articles,…
Xbrane Biopharma and its co-development partner STADA have entered into an exclusive licensing agreement with Bausch + Lomb to commercialize Xlucane, a Lucentis (ranibizumab) biosimilar candidate, in the United States and Canada. The companies aim to obtain regulatory approval of all currently apAlready a subscriber Login You have read all…
Cantargia has announced that its IND application regarding the antibody CAN04 has been approved by the US FDA. CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer Already a subscriber Login You have read…
